secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001213900-22-045601
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics Q2 2022 net loss $8.5M ($0.80/share); cash $112.8M
-----------------------------------------------------------------------

- Net loss of $8.5M ($0.80 per share) vs $12.8M ($1.14) in Q2 2021.
- Cash, cash equivalents and marketable debt securities of $112.8M as of June 30, 2022.
- R&D expenses decreased to $3.1M from $5.9M; G&A decreased to $5.6M from $6.9M.
- ADVANCED-1 Phase 1 trial of TARA-002 in NMIBC enrollment progressing; Trials in Progress poster presented at ASCO June 2022.
- EMA granted orphan drug designation to TARA-002 for lymphatic malformations; Phase 2 trial planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022045601/0001213900-22-045601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022045601/ea163937-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-045601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer